

STIC-ILL

4267819

Vol No

32402

From: Holleran, Anne
Sent: Tuesday, September 04, 2001 6:03 PM
To: STIC-ILL
Subject: refs. for 09/251,133

Examiner: Anne Holleran
Art Unit: 1642; Rm 8E03
Phone: 308-8892
Date needed by: ASAP

Please send me copies of the following :

1. Chien, J. et al. Mol. and Cell. Endocrinology (2001) 181(1-2): 69-79
2. Chien, J. et al. Int. J. of Cancer (2001) 91(1): 46-54
3. Chien, J. et al. Oncogene (1999) 18(22): 3376-3382
4. Wong, E.C.C. et al. Proc. Amer. Assoc. for Cancer Res. (1997) 38: 288
5. Rayford, W. et al. Prostate (1997) 30(3): 160-166
6. Xue-Zhang, Q. et al. Endocrine (1995) 3(6): 445-451
7. Shah, G.V. et al. Endocrinology (1994) 134(2): 596-602
8. Rayford, W. et al. J. of Urology (1994) 151(5 suppl): 490A
9. Rayford, W. et al. J. of Urology (1993) 149(4 suppl): 479A
10. Shah, G.V. et al. Prostate (N.Y.) (1992) 21(2): 87-97
11. Sagol, O. et al. Annals of Medical Sciences (1999) 8(1): 14-21
12. Sussenot, O. et al. Prostate (1998) 36(suppl. 8): 43-51
13. Hanna, F.W. et al. J. Endocrinol. (1997) 152(2): 275-281
14. Sim, S.J. et al. Annals of Clinical and Laboratory Science (1996) 26(6): 487-495
15. Watanabe, K. et al. Fukushima J. Medical Science (1995) 41(2): 141-152
16. Esik, O. et al. European J. Gynaecological Oncology (1994) 15(3): 211-216

1469122

BEST AVAILABLE COPY

I. EDSON PONTES
Managing Editor
(Editorial Office)
Department of Urology
University School of Medicine
Professional Building
50 John R., Suite 1017
Detroit, MI 48201

JOHN T. ISAACS
Associate Editor
Baltimore, Maryland

Fritz H. Schroeder
Rotterdam, Holland

Ciro Servadio
Petah-Tiqva, Israel

Keizo Shida
Gunma-ken, Japan

Jun Shimazaki
Chiba-Shi, Japan

Roy G. Smith
Houston, Texas

Martin Tenniswood
Ottawa, Canada

Aurelio C. Usón
Madrid, Spain

Alex Vermeulen
Ghent, Belgium

Klaus-Dieter Voigt
Hamburg, Germany

Hiroki Watanabe
Kyoto, Japan

Raphael J. Witorsch
Richmond, Virginia

George L. Wright
Norfolk, Virginia

Hidetoshi Yamanaka
Maebashi, Japan

clients, is granted by Wiley-Liss,
Reporting Service, provided that

ley & Sons, Inc., 605 Third Avenue,
tment, 9th floor, 605 Third Avenue,

nal Subscription Rate: For 1992,
ard, bank draft or money order. All
ge of Address: Please forward to
ress. Claims for Missing Issues:
close a copy of the mailing label or
sses have been sustained in transit
nue, New York, NY 10158. If claims
ution, John Wiley & Sons, Inc., 605
the first issue has been mailed.
Chemical Abstracts Institute of
ference Update.

tribution, John Wiley & Sons, Inc.,

Presence of Calcitonin-Like Immunoreactivity (iCT) in Human Prostate Gland: Evidence for iCT Secretion by Cultured Prostate Cells

Girish V. Shah, Mark J. Noble, Mark Austenfeld, John Weigel, L.J. Deftos,
and Winston K. Mebust

*Departments of Urologic Surgery (G.V.S., M.J.N., M.A., J.W., W.K.M.) and Physiology
(G.V.S.), University of Kansas Medical Center, Kansas City, Kansas, and Kansas City
Veterans Administration Medical Center (G.V.S., M.J.N., M.A., J.W., W.K.M.),
Kansas City, Missouri; Department of Medicine, University of California, San Diego
and San Diego VA Medical Center, La Jolla (L.J.D.)*

Immunoreactive calcitonin (iCT) has been detected in human prostate tissue extracts as well as seminal plasma. The present studies were undertaken to examine whether iSCT (immunoreactive salmon CT-like human peptide) co-exists with iHCT (thyroid CT-like substance) in human prostate tissue extracts, and whether these substances are secreted by primary prostate cells in culture. Since the local secretion of these substances seems to increase in some neoplasms, a second objective of the study was to examine whether basal secretion of iCTs from primary prostate cells is increased in carcinoma. The present results have shown that both iHCT and iSCT were present in prostate tissue extracts. The mean iHCT levels in extracts of benign hyperplastic prostates (BPH) were 0.59 ng/g prostate, and these were significantly lower than iHCT concentrations in prostatic carcinoma (PC) (2.53 ng/g). No significant differences in their iSCT contents were observed. However, the results from culture of over 90 individual prostate tissue specimens from BPH or PC indicate that primary prostate cells secreted detectable quantities of iSCT and the basal release of this material from PC prostate cultures was almost four-fold higher than that from BPH prostate cultures.

These results suggest that a CT-like immunoreactive material is secreted by primary prostate cells in culture, and the basal secretion of this material is significantly higher in PC cells as compared to BPH cells. Endogenous secretion of prostatic CT, and the elevation of its expression in PC suggest that it may serve as a regulatory factor in the pathophysiology of the prostate gland. © 1992 Wiley-Liss, Inc.

Key words: calcitonin, prostate cells, culture, BPH, prostatic carcinoma

INTRODUCTION

Calcitonin (CT), a 32-amino acid peptide hormone, is secreted by parafollicular or C cells of the thyroid gland. It inhibits bone resorption and increases renal clearance of sodium, phosphate and calcium [1]. In addition to CT, various related pep-

Received for publication December 11, 1991; accepted April 6, 1992.

Address reprint requests to Girish V. Shah, Ph.D., Department of Surgery, Division of Urology, University of Kansas Medical Center, Rainbow Boulevard at 39th Street, Kansas City, KS 66103.

© 1992 Wiley-Liss, Inc.

tides or gene products have been detected in several organs and body fluids. For example, CT gene-related peptide (CGRP) is produced in neuronal cells by alternative processing of the primary CT gene transcript. Two different CGRP peptides, CGRP- α and CGRP- β , have been described in the human and rat brain, and seem to be products of two different CT genes [2]. Ketacalcin, a carboxy-terminal flanking peptide of the CT-precursor, has also been identified in body fluids, and is considered as a secretory product of CT gene [2]. In addition, the presence of a peptide referred to as salmon (S)CT-like peptide has been demonstrated in humans and several other mammalian species, and its presence in normal human sera, milk, the brain, and the thyroid gland has been demonstrated by specific antibodies [3–6]. Besides their predominant presence in the thyroid gland, CT and related peptides are also present in large concentrations in seminal plasma, and high affinity binding sites for SCT are identified in the neck and mid-piece region of human spermatozoa [7–10]. This suggests that CT and related peptide(s) may have a physiological role in regulation of sperm activity and other male reproductive processes.

Seminal CT levels in split ejaculate correlate with zinc and other prostatic secretions [10]. These findings indicate that CT in seminal plasma may originate from the prostate gland. Subsequent studies have shown that measurable quantities of immunoreactive CT are present in prostate tissue extracts, and the CT-immunopositive cells have been localized among neuroendocrine cell populations of the prostate gland [11–15]. Accumulated CT levels in tissue extracts of benign hyperplastic prostate (BPH) are significantly lower than normal prostate tissue [12]. In contrast, relative population of CT-immunopositive and other neuroendocrine cells increases with progression of prostatic adenocarcinoma (PC) [15]. This raises a possibility that alterations in prostate CT expression may have a functional significance in the pathophysiology of the prostate gland. However, there is no direct evidence for biosynthesis of CT or related peptides in the prostate gland, or for whether their local secretion is altered in prostate dysfunction.

Using recently developed specific and sensitive RIAs for HCT and SCT [6,16], we have investigated 1) whether a SCT-like peptide co-exists with HCT in seminal plasma and prostate tissue extracts, 2) whether CTs are synthesized and released by benign and malignant prostate cells, and 3) whether the rate of their basal secretion is altered in malignancy.

MATERIALS AND METHODS

Prostate Tissue Specimen

Human prostatic tissue specimens obtained were either from biopsy or from freshly resected glands removed during transurethral prostatectomy or radical prostatectomy. The surgeries were performed at the University of Kansas Medical Center and the Kansas City Veterans Administration Hospital. The age of this patient population ranged from 48 to 71 years (mean age: 63 years). The patients did not receive any hormonal or drug treatment prior to the collection of tissue specimens. Appropriate informed consent was obtained in all cases.

Semen Samples

Semen samples were obtained from healthy male volunteers with normal spermograms. The samples were obtained in polyethylene cups after 3–5 days of absti-

body fluids. For cells by alterna-CGRP peptides, ain, and seem to terminal flanking and is considered peptide referred and several other ie brain, and the J. Besides their are also present sites for SCT are oa [7–10]. This in regulation of

1 other prostatic may originate from sole quantities of CT-immunopos- is of the prostate hyperplastic pros- [2]. In contrast, e cells increases a possibility that nce in the patho- ence for biosyn- either their local

and SCT [6,16], HCT in seminal and released by r basal secretion

biopsy or from or radical pros- s Medical Center this patient pop- ts did not receive ecimens. Appro-

with normal sper- -5 days of absti-

nence. The samples were allowed to liquify at room temperature for 30 min, were centrifuged to remove sperm and sediments, and were stored frozen at -20°C.

Extraction of Seminal Plasma and Prostate Tissues for RIA

Semen and prostate tissue specimens from BPH and cancer patients were processed using a modification of the method of Tobler et al. [17]. In brief, after determining the wet weight of frozen tissues (40–110 mg), tissues or seminal plasma samples were suspended in 2 M acetic acid (1:20 wt/vol for prostate tissues and vol/vol for seminal plasma) and heated at 85°C for 5 min. The tissues were homogenized in a dounce homogenizer, and resulting supernatants were centrifuged at 36,000 rpm for 30 min at 4°C. The clear supernatant was passed 20 times through Sep-Pak C₁₈ cartridges (Waters associates, Milford, MA) activated with 10 ml methanol and equilibrated with 20 ml 0.1% trifluoroacetic acid (TFA) in water (vol/vol). The cartridges were washed with 40 ml 0.1% TFA, and CT fraction was eluted in 15 ml 80% methanol in water containing 0.1% TFA. The samples were lyophilized after addition of 10 ml 0.1 M acetic acid. Our previous studies suggest that the recovery of exogenously added SCT and HCT in a sample by this method ranges between 75 and 106% [6].

Tissue Culture

Needle biopsy tissue and transurethrally resected prostate chips were collected aseptically and placed individually in sterile transport medium [RPMI-1640 without fetal bovine serum (FBS)]. These fragments were transported to the laboratory, a portion of these fragments were fixed and frozen for immunohistochemistry, and the remaining fragments were individually cultured as described before [18,19]. In brief, the tissue was cut to remove the burned areas and minced into 1 × 2 × 1 mm sections. Approximately, eight of such sections were evenly distributed in a 25 cm² tissue culture flask (Falcon, Oxnard, CA). Culture medium, 1.0 ml (basic RPMI-1640 medium supplemented with L-glutamine, 10% newborn calf serum, 25 mM Hepes, 10 ng/ml epithelial growth factor, 5 ng/ml insulin, 5 ng/ml transferrin, 5 ng/ml selenium, 50 units/ml penicillin, 50 µg/ml streptomycin, 10 ng/ml 5 α-androstan-17-ol-3-one), was then gently added to each flask so as not to shake the explants off, and the explants were allowed to plate for 7 days at 37°C with 5% CO₂ in a humidified atmosphere. After the initial 1st week, the culture medium was replaced twice every week until the flask became confluent with cells. Under our experimental conditions, it takes approximately 5 to 6 weeks for the cells to grow to confluence. Separate pools of media were prepared for feeding each patient's cells to avoid risk of cross-contamination. At confluence, the cells were washed and the culture medium was replaced with basal incubation medium (basic RPMI 1640 containing 1-glutamine, 0.3% BSA, 10 mM Hepes, gentamicin, and bacitracin). The cells were incubated for 24 h and the spent media were collected and stored at -80°C until assayed for HCT and SCT contents by RIA. The cells (viability > 90% by trypan blue exclusion) were then harvested and counted with a hemocytometer. Our earlier studies suggest that a confluent 25 cm² tissue culture flask contains approximately 0.5–0.6 million primary prostate cells.

Radioimmunoassays

Both HCT and SCT RIAs employed a similar non-equilibrium protocol as described before [6,16].

Synthetic human CT (Peninsula Laboratories, Belmont, CA) was iodinated with ^{125}I to a specific activity of 33 $\mu\text{Ci}/\mu\text{g}$ with chloramin T, and was purified as described before [17]. Anti-HCT rabbit serum (LD-2, kindly provided by Dr. L. Deftos, University of California, San Diego) was used at a dilution of 1:3,500. The assay provides a detection limit (2 SD from B_0) of 2 pg/tube using synthetic HCT as a reference preparation. SCT RIA was essentially the same as described before [6]. The detection limit of the assay is 8–16 pg/tube of synthetic SCT. Anti-SCT rabbits serum (GCT1) was obtained following immunization with synthetic SCT (1-34)-keyhole limpet hemocyanin conjugate [6]. No cross-reaction of HCT and SCT occurred in two homologous RIAs in amounts as high as 75 ng of either peptide, and neither anti-serum recognized CT gene-related peptide. Further characterization of the antisera has been described previously [6,16].

All seminal plasma or prostate tissue extracts as well as spent media from cultured prostate cells were analyzed for the presence of HCT-like and SCT-like immunoreactivity. The results are expressed as ng CT Eq/g tissue or ml seminal plasma and pg CT Eq released per million cells. Intraassay variations for the assays were determined by running selected specimens in at least six to eight replicates. Parallelism between reference preparations and a pool of seminal plasma extracts or culture media was examined by running serial dilutions of the samples with serial dilutions of synthetic HCT or SCT in an assay.

Immunocytochemistry

Dispersed prostate cells were stained for SCT immunocytochemistry according to the modified method of Denef et al. [20]. Cells (5×10^5) suspended in 100 μl RPMI were allowed to attach for 24 h (at 37°C) to a poly-L-lysine coated glass coverslip placed in an individual well of a 6-well culture plate. After the incubation, the cells were fixed for 30 min (at room temperature) with 4% formalin in PBS (pH 7.3), washed three times in PBS, and stored in PBS (at 4°C) containing 5% normal goat serum. For immunostaining, the cells were incubated with 3% H_2O_2 for 10 min at room temperature to inactivate the endogenous peroxidase activity. The cells were then incubated sequentially with 1) blocking solution (PBS containing 1% bovine serum albumin, 0.3% Triton X-100, 0.2% nonfat dry milk, 0.01% sodium azide) for 10 min at room temperature; 2) anti-SCT serum (1:500, diluted in the blocking buffer) overnight at room temperature; 3) goat anti-rabbit IgG conjugated with horseradish peroxidase (Cappel Laboratories, West Chester, PA; diluted 1:20 in the blocking buffer) for 1 h at room temperature; 4) peroxidase-antiperoxidase incubation (Cappel Laboratories; 1:80 in the blocking buffer) for 1 h at room temperature. The color was developed with 10 mg diaminobenzidine tetrachloride in Tris-NaCl containing 0.06% H_2O_2 for 30–40 min.

A parallel set of control slides was processed similarly, but in place of primary anti-SCT serum, the slides received equivalent amounts of either preimmune serum or anti-SCT serum preabsorbed with 10 μM SCT (peptide control). Staining with anti-HCT was not performed, since the results from the culture experiments indicated a lack of detectable iHCT release by prostate cells.

Statistical Analysis

The data were analyzed by analysis of variance and the statistical significance was derived from Student's *t*-test.

was iodinated with I^131 and was purified as provided by Dr. L. on of 1:3,500. The β synthetic HCT as described before [6]. Anti-SCT rabbits synthetic SCT (1-34)-HCT and SCT or either peptide, and characterization of

spent media from HCT-like and SCT-like tissue or ml seminal dilutions for the assays to eight replicates. plasma extracts or samples with serial

chemistry according to standard procedures in 100 μl lysine coated glass after the incubation, formalin in PBS (pH 7.4) containing 5% normal horse serum and 3% H_2O_2 for 10 min at room temperature. The cells were stained with 1% bovine serum albumin (bovine β -naphthyl azide) for 1 h (the blocking buffer) and with horseradish peroxidase (HRP) (1:20 in the blocking buffer (Cappel culture). The color was developed in a medium containing 0.06%

in place of primary preimmune serum (control). Staining with peroxidase indicated

statistical significance

TABLE I. Concentrations of Immunoreactive Calcitonins (iHCT and iSCT) in Seminal Plasma and Prostate Tissue Extracts

	iHCT ($\bar{X} \pm \text{SEM}$)	iSCT ($\bar{X} \pm \text{SEM}$)	n
Seminal plasma (ng/ml)	0.78 \pm 0.28	0.048 \pm 0.023	
Prostate extracts (ng Eq/g tissue)			
BPH	0.59 \pm 0.16*	0.98 \pm 0.19	n = 10
(range)	(0.16–1.65)	(0.39–1.89)	
PC	2.53 \pm 0.97*	0.98 \pm 0.18	n = 9
(range)	(0.24–10.63)	(0.20–1.73)	

*Significantly different, $P < .05$ (paired t-test).

RESULTS

Presence of CTs in Prostatic Tissue Extracts and Seminal Plasma

The detection limit of HCT RIA (2 SD from B_0) was 1.95 pg of synthetic HCT and the intraassay variability was less than 5%. In the initial assay, a pool of seminal plasma extracts was serially diluted with synthetic HCT, and the extract exhibited parallelism with HCT suggesting a similarity in the antigenicity of seminal HCT and synthetic HCT (data not shown). Likewise, a dilution curve of this extract also exhibited parallelism with a dilution curve of synthetic SCT in a SCT RIA. Subsequently, all prostate tissue and seminal plasma extracts were analyzed in a single assay to avoid interassay variability. We could not obtain normal prostate tissue specimens for the assay, but altogether 19 diseased prostate tissues [prostate cancer (PC)-9; benign prostatic hypertrophy (BPH)-10] and 5 seminal plasma samples were extracted and analyzed for CTs by RIA. The results are presented in Table I.

All prostate tissue and seminal plasma extracts contained detectable quantities of HCT-like (iHCT) as well as SCT-like immunoreactivity (iSCT), and exhibited a wide range in their peptide content. While HCT content in BPH tissues was significantly lower than extracts from PC, there were no significant differences in their iSCT content (Table I). The levels of iHCT in tissue extracts and seminal plasma in the present study are comparable to previously reported results of others [8,12].

Release of CTs by Primary Prostate Cells

In all, 91 primary prostate cells from individual BPH or PC specimens were grown to confluence. The cells were incubated with the basal medium for 24 h, and the spent media were analyzed for CTs by RIAs.

The spent media samples from individual prostate cultures were analyzed for HCT, and none of the 91 cell culture media samples exhibited detectable amounts of iHCT. Similar results were obtained when these samples were reassayed with a commercially available HCT RIA kit (INC-star, Stillwater, MN).

In contrast to the absence of detectable amounts of iHCT, a majority of the culture media samples contained measurable quantities of iSCT, and a dilution curve of pooled culture media was parallel to the displacement curve of synthetic SCT (Fig. 1). Of the total 91 cell culture media tested, iSCT levels in 22 samples were below the detection limit of the assay. Eighteen of these 22 samples were from BPH prostates, while the remaining 4 were obtained from PC. The results presented in Figure 2 show that prostate cancer cells released a mean of 114 pg iSCT Eq/million




Fig. 1. Parallel displacement of ^{125}I -SCT binding to anti-SCT by synthetic SCT and prostate culture media in a SCT RIA.

cells/24 h, which is significantly higher than 34 pg iSCT Eq released by cells obtained from BPH prostates ($P < .05$, unpaired t-test).

Immunocytochemistry

At the end of the cell culture experiment, the prostate cells were dissociated from the culture flask. The cells exhibited a typical spherical appearance and good viability (>90%). Immunocytochemical study indicates that a small population of cells stained positively for iSCT, and as expected, staining in the immunopositive CT cells was localized to the cytosol (Fig. 3). Neither preimmune serum control nor peptide control exhibited significant staining (data not shown).

DISCUSSION

The presence of high concentrations of immunoreactive HCT in human seminal plasma and prostate tissue extracts has been demonstrated, and the present results are consistent with these findings [7-12]. In addition, the present study reveals the presence of SCT-like immunoreactivity in prostate and seminal plasma extracts. A




Fig. 2. Immunoreactive SCT concentrations in culture media from primary prostate cells obtained from prostatic carcinoma (PC) and benign prostatic hypertrophy (BPH). Each data point represents the mean \pm SEM of n samples ($n_{BPH} = 41$; $n_{PC} = 50$). * $P < .05$ (comparison between BPH and PC by unpaired t-test).

similar peptide has been detected in normal humans as well as in patients with small cell carcinoma of the lung [4,5,21,22]. While this peptide is present only in trace amounts in the thyroid, it is more abundant in human brain [4]. Although the precise sequence of SCT-like human peptide remains to be determined, the peptide immunoreacts with the antiserum raised against SCT, co-elutes with synthetic SCT on reverse phase high performance liquid chromatography, and messenger RNA preparations from the thyroid gland of medullary thyroid carcinoma patients direct the synthesis of an anti-SCT serum precipitable peptide in vitro [4,22]. Binding sites recognizing salmon, but not human, CT have been recognized in various regions of brain as well as human spermatozoa, and ^{125}I -SCT also binds with high affinity to CT receptors in the bone and the kidney [23-25]. The presence of iHCT and iSCT in seminal plasma suggests that the peptides may have a role in regulation of sperm activity and other processes leading to fertilization. However, any direct effect of HCT on sperm activity or semen quality has not been suggested [7,8,24]. In contrast, SCT specifically inhibits sperm motility at subnanomolar-nanomolar concentrations. This action of SCT seems to be receptor-mediated and specifically affects calmodulin-dependent intracellular mechanisms [24]. Thus, the presence of iSCT in seminal plasma suggests that it may serve as an endogenous ligand for SCT-receptors on human spermatozoa and regulate fertility by preventing premature activation of human spermatozoa.

In addition to their potential role in regulation of spermatozoal activity, CT-like peptides may have a role in the physiology and pathophysiology of the prostate gland. Similar to the previous findings of others, the present results suggest that accumulated iHCT content in hyperplastic prostate is significantly lower than malignant prostate tissue [18]. However, iSCT levels were similar in both groups. Since the tissue specimens in the present study were collected from several patients of varied age and

T and prostate culture

d by cells obtained

were dissociated
earance and good
nall population of
nnunopositive CT
serum control nor

in human seminal
present results are
study reveals the
asma extracts. A




Fig. 3. Photomicrograph of cultured prostate cells immunostained with anti-SCT serum. Dark immunoperoxidase-stained CT-immunopositive cells (indicated by arrow) are distributed among lighter, hematoxylin-stained prostate cells. The cells had round or fusiform cell bodies, and some had extended neurite-like processes. Magnification: $\times 200$.

health status, these results may have been influenced by wide individual variations in tissue and serum iCTs in patient populations [26]. To examine whether iCTs detected in tissue extracts are of prostatic origin or are acquired from circulation, we have tested their presence in secretions from primary prostate cultures. Since cells from individual prostate specimens were cultured under identical conditions, and tested for CT release after several weeks of culture and several media changes, concentrations of CTs released into the medium during the test period may indicate their endogenous secretory activity. The results indicate the absence of detectable iHCT in spent media, and suggest that iHCT in prostate tissue extracts may have been derived from circulation. Alternatively, iHCT-secreting prostate cells do not survive under our experimental conditions. In contrast, iSCT was present in the majority of the prostate culture media, and its secretion from cancer cells was almost four-fold higher than benign prostate cells. Thus, the initial findings suggest that the endogenous CT-like immunoreactive material secreted by primary prostate cells shares antigenic sites with SCT. Moreover, the extent of increase in iSCT secretion by cancer cells seems similar to that seen in prostate tumor markers such as prostate-specific antigen (PSA) and prostate acid phosphatase (PAP) [27]. Increased iSCT secretion has also been reported from lung cancer cells, and this was found to be parallel to other tumor markers such as carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) [21]. This raises a possibility that prostatic CT may serve as a novel tumor marker for



SCT serum. Dark immunoreactivity is seen among lighter, heterogeneous background. Some had extended

individual variations in the amount of iCTs detected in circulation, we have observed. Since cells from various sites, and tested for various concentrations of their endogenous iCT in spent media, derived from cultures under our experimental conditions of the prostate were four-fold higher than endogenous CT-like antigenic sites with normal cells seems similar to the antigen (PSA) and has also been parallel to other tumor specific enolase (NSE) as a tumor marker for

prostate cancer; however, a more detailed study to examine parallelism between increases in prostatic CT with PSA and PAP will be necessary.

CT has been detected in numerous extrathyroidal tissues such as the brain, the gastrointestinal tract, the lungs, and the prostate gland [28]. Considering the presence of CT in diverse organs, it is conceivable that thyroid CT may be largely responsible for the maintenance of Ca^{2+} homeostasis and skeletal structure, whereas locally synthesized CTs may serve as paracrine regulatory peptides in respective organs. CT gene products are also expressed by several non-thyroid human neoplasms, and expression of these products as well as CT receptors seem to increase with progression of the tumors [28-31]. This suggests that CTs may play a role in regulation of growth or secretory function of neoplastic cells, and various growth-promoting effects of CT support this possibility. For example, *in vivo* administration of SCT induces testicular, brain, and renal ornithine decarboxylase, a key enzyme associated with growth processes and cell cycle progression [32]. Recent evidence has shown that the action of CT in a target cell may vary according to the position of the cell in the cell cycle. For example, CT stimulates ouabain-sensitive $\text{Na}^+ - \text{K}^+$ adenosine triphosphatase in pig kidney cells when the cells are in G₂ phase, and inhibits this enzyme when the cells are in S phase [33]. These cell cycle-linked and biologically opposite actions of CT in the same cell suggest that the peptide may play an important regulatory role during periods of rapid growth such as entry of a quiescent cell into cell cycle and cell proliferation. Similar actions of CT in prostate cells may be of importance in regulation of growth during tumor formation and tumor growth.

In conclusion, the present study has shown that primary prostate cell secrete detectable amounts of CT-like immunoreactivity (prostatic CT) in culture. The cultures from prostatic carcinoma secrete significantly higher quantities of prostatic CT as compared to the cultures from BPH prostates. These findings suggest that prostatic CT may serve as a novel tumor marker for prostate cancer. Endogenous secretion of prostatic CT, coupled with the presence of its high affinity binding sites in the prostate gland (Shah et al., in preparation) and spermatozoa, raise a possibility that prostatic CT may play a paracrine regulatory role in the pathophysiology of the prostate gland and also affect sperm activity. Further studies are necessary to identify this product and to understand the regulation of its secretion and biological effects in the prostate gland.

ACKNOWLEDGMENTS

The authors thank Ms. Vicki Edelman and Mr. Mukund B. Jadhav for expert technical assistance, and Ms. Jeanne Selby for secretarial help. This work was supported by SEP grant from Marion Merrel Dow and the NCI, NIH, and the Department of Veterans Affairs (L.J.D.).

REFERENCES

- Potts JT, Jr, Deftos LJ: Parathyroid hormone, calcitonin, vitamin D, bone and bone mineral metabolism. In Bondy PK, (ed): "Duncan's Diseases of Metabolism." Philadelphia: W.B. Saunders, 1974, p 1036.
- Fischer JA, Born W: Novel peptides from the calcitonin gene: expression, receptors and biological function. Peptides (Fayetteville) 6(Suppl 3):265-271, 1985.

3. Perez Cano R, Grgis SI, MacIntyre I: Further evidence for calcitonin gene duplication: The identification of two different calcitonins in a fish, a reptile and two mammals. *Acta Endocrinol (Copenh)* 100:256-261, 1982.
4. Fischer JA, Tobler PH, Henke H, Tschopp FA: Salmon and human calcitonin-like peptides coexist in the human thyroid and brain. *J Clin Endocrinol Metab* 57:1314-1315, 1983.
5. Tobler PH, Tschoop FA, Dambacher MA, Fischer JA: Salmon and human calcitonin-like peptides in man. *Clin Endocrinol* 20:253-259, 1984.
6. Shah GV, Kascsoh B, Seshadri R, Grosvenor CE, Crowley WR: Presence of calcitonin-like peptide in rat milk: Possible physiological role in regulation of neonatal prolactin secretion. *Endocrinology* 125:61-67, 1989.
7. Bucht E, Arver S, Sjoerberg HE: Immunoextracted calcitonin from human seminal plasma constitutes different forms. *Acta Physiol Scand* 126:289-293, 1986.
8. Maier U, Woloszczuk W, Schuh H, Zechner O: Calcitonin- and ketacalcin-like immunoreactivity in human seminal plasma. *Exp Clin Endocrinol* 88:89-94, 1986.
9. Foresta C, Caretto A, Indino A, Betterle C, Scandellari C: Calcitonin in human seminal plasma and its localization on human spermatozoa. *Andrologia* 18:470-472, 1986.
10. Sjoerberg HE, Arver S, Bucht E: High concentration of immunoreactive calcitonin of prostatic origin in human semen. *II* 110:101-102, 1980.
11. Shulkes A, Fletcher DR, Rubinstein C, Ebeling PR, Martin TJ: Production of calcitonin gene-related peptide, calcitonin and PTH-related protein by a prostatic adenocarcinoma. *Clin Endocrinol* 34: 387-393, 1991.
12. Davis NS, diSant'Agnese PA, Ewing JF, Mooney RA: The neuroendocrine prostate: Characterization and quantitation of calcitonin in the human prostate gland. *J Urol* 142:884-888, 1989.
13. diSant'Agnese PA: Calcitonin-like immunoreactive and bombesin-like immunoreactive endocrine-paracrine cells of the human prostate. *Arch Pathol Lab Med* 110:412-416, 1986.
14. diSant'Agnese PA, deMesy Jensen KL: Calcitonin, ketacalcin and calcitonin gene-related peptide in the human prostate: An immunocytochemical and immuno-electron microscopic study. *Arch Pathol Lab Med* 113:790-796, 1989.
15. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L: Peptide hormone- and serotonin-immunoreactive tumor cells in carcinoma of the prostate. *Pathol Res Pract* 182:298-307, 1987.
16. Pavlinac DM, Lenhard LW, Parthemore JG, Deftos LJ: Immunoreactive calcitonin in human cerebrospinal fluid. *J Clin Endocrinol Metab* 50:717-720, 1980.
17. Tobler PH, Johl A, Born W, Maier R, Fischer JA: Identity of calcitonin extracted from normal human thyroid glands with synthetic human calcitonin-(1-32). *Biochim Biophys Acta* 707:59-64, 1982.
18. Clarke SM, Merchant DJ: Primary cultures of human prosatic epithelial cells from transurethral resection specimens. *The Prostate* 1:78-84, 1980.
19. Noble MJ, Lee SH, Mebus WK: Role of the matrix in modifying the growth of prostatic epithelial cells in vitro. *Clev Clin Q* 51:411-414, 1984.
20. Denef C, Hautekeet E, de Wolf A, Vanderschueren B: Pituitary basophils from immature male and female rats: Distribution of gonadotrophs and thyrotrophs as studied by unit gravity sedimentation. *Endocrinology* 103:724-728, 1978.
21. Gropp C, Luster W, Havemann K: Salmon and human calcitonin like material in lung cancer. *Br J Cancer* 51:897-901, 1985.
22. Lasmoles F, Julliene A, Day F, Minvielle S, Milhaud G, Moukhtar MS: Elucidation of the nucleotide sequence of chicken calcitonin mRNA: Direct evidence for the expression of a lower vertebrate calcitonin-like gene in man and rat. *EMBO J* 4:2603-2607, 1985.
23. Henke H, Tschoop FA, and Fischer JA: Localization of salmon calcitonin binding sites in rat brain by autoradiography. *Brain Res* 360:165-169, 1985.
24. Gnessi L, Silvestroni L, Fabbri A, Moretti C, Panerai AE, Bonifacio V, Fraioli F: Salmon calcitonin inhibits human sperm motility in vitro. *Biochem Biophys Res Commun* 125:199-204, 1984.
25. Azria M: "The Calcitonins." Basel: Karger, 1989, p 152.
26. Bezwoda W, Derman D, Bothwell T, MacPhil P, Levin J, De Moor N: Significance of serum concentrations of carcinoembryonic antigen, ferritin and calcitonin in breast cancer. *Cancer* 48: 1623-1625, 1981.
27. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N: Prostate

- specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. *J Urol* 141:1076-1083, 1989.
28. Imura H: Ectopic hormone production viewed as an abnormality in regulation of gene expression. *Adv Cancer Res* 33:39-75, 1980.
 29. Austin LA, Heath H: Calcitonin physiology and pathophysiology. *N Engl J Med* 304:269-278, 1981.
 30. Findlay DM, Michelangeli VP, Eisman JA, Frampton RJ, Moseley JM, MacIntyre I, Whitehead R, Martin TJ: Calcitonin and 1,25-dihydroxy vitamin D receptors in several human breast cancer lines. *Cancer Res* 40:4764-4767, 1980.
 31. Martin TJ, Findlay DM, Michelangeli VP, Moseley JM, Eisman JA, MacIntyre I: Significance of calcitonin production and action in cancer. In: Cumming IA, Funder JW, Mendelsohn FAO (eds): "Endocrinology," Amsterdam: Elsevier, 1980, p 657.
 32. Nakhla AM: Calcitonin induces ornithine decarboxylase in various rat tissues. *Mol Cell Endocrinol* 52:263-265, 1987.
 33. Chakraborty M, Chatterjee D, Kellokumpu S, Rasmussen H, Baron R: Cell cycle-dependent coupling of the calcitonin receptor to different G proteins. *Science* 251:1078-1082, 1991.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.